Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease progression. However, nintedanib was not associated with a...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 January 2020
|
| In: |
Respiratory research
Year: 2020, Jahrgang: 21 |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-020-1298-1 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-020-1298-1
|
| Verfasserangaben: | Michael Kreuter, Wim A. Wuyts, Marlies Wijsenbeek, Sabrina Bajwah, Toby M. Maher, Susanne Stowasser, Natalia Male, Wibke Stansen, Nils Schoof, Leticia Orsatti and Jeffrey Swigris |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1693850524 | ||
| 003 | DE-627 | ||
| 005 | 20230427031713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200402s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-020-1298-1 |2 doi | |
| 035 | |a (DE-627)1693850524 | ||
| 035 | |a (DE-599)KXP1693850524 | ||
| 035 | |a (OCoLC)1341313677 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kreuter, Michael |d 1972- |e VerfasserIn |0 (DE-588)122645995 |0 (DE-627)082066795 |0 (DE-576)293362742 |4 aut | |
| 245 | 1 | 0 | |a Health-related quality of life and symptoms in patients with IPF treated with nintedanib |b analyses of patient-reported outcomes from the INPULSIS® trials |c Michael Kreuter, Wim A. Wuyts, Marlies Wijsenbeek, Sabrina Bajwah, Toby M. Maher, Susanne Stowasser, Natalia Male, Wibke Stansen, Nils Schoof, Leticia Orsatti and Jeffrey Swigris |
| 264 | 1 | |c 30 January 2020 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.04.2020 | ||
| 520 | |a In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease progression. However, nintedanib was not associated with a benefit in health-related quality of life (HRQoL) assessed using the St George’s respiratory questionnaire (SGRQ). We aimed to further examine the impact of IPF progression on HRQoL and symptoms, and to explore the effect of nintedanib on HRQoL in patients from the INPULSIS® trials stratified by clinical factors associated with disease progression. | ||
| 700 | 1 | |a Wuyts, Wim A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wijsenbeek, Marlies |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bajwah, Sabrina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Maher, Toby M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stowasser, Susanne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Male, Natalia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stansen, Wibke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schoof, Nils |e VerfasserIn |4 aut | |
| 700 | 1 | |a Orsatti, Leticia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Swigris, Jeffrey |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d London : BioMed Central, 2001 |g 21(2020) Artikel-Nummer 36, 12 Seiten |h Online-Ressource |w (DE-627)326646485 |w (DE-600)2041675-1 |w (DE-576)107014823 |x 1465-993X |7 nnas |a Health-related quality of life and symptoms in patients with IPF treated with nintedanib analyses of patient-reported outcomes from the INPULSIS® trials |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g extent:12 |a Health-related quality of life and symptoms in patients with IPF treated with nintedanib analyses of patient-reported outcomes from the INPULSIS® trials |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12931-020-1298-1 |x Resolving-System |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200402 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 122645995 |a Kreuter, Michael |m 122645995:Kreuter, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK122645995 |e 950000PK122645995 |e 950900PK122645995 |e 50000PK122645995 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1693850524 |e 3617706460 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"roleDisplay":"VerfasserIn","given":"Michael","display":"Kreuter, Michael","family":"Kreuter","role":"aut"},{"role":"aut","family":"Wuyts","given":"Wim A.","roleDisplay":"VerfasserIn","display":"Wuyts, Wim A."},{"display":"Wijsenbeek, Marlies","roleDisplay":"VerfasserIn","given":"Marlies","family":"Wijsenbeek","role":"aut"},{"role":"aut","family":"Bajwah","given":"Sabrina","roleDisplay":"VerfasserIn","display":"Bajwah, Sabrina"},{"given":"Toby M.","roleDisplay":"VerfasserIn","display":"Maher, Toby M.","family":"Maher","role":"aut"},{"family":"Stowasser","roleDisplay":"VerfasserIn","given":"Susanne","display":"Stowasser, Susanne","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Natalia","display":"Male, Natalia","family":"Male","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Wibke","display":"Stansen, Wibke","family":"Stansen","role":"aut"},{"family":"Schoof","roleDisplay":"VerfasserIn","display":"Schoof, Nils","given":"Nils","role":"aut"},{"role":"aut","display":"Orsatti, Leticia","roleDisplay":"VerfasserIn","given":"Leticia","family":"Orsatti"},{"family":"Swigris","roleDisplay":"VerfasserIn","given":"Jeffrey","display":"Swigris, Jeffrey","role":"aut"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib","title":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib","subtitle":"analyses of patient-reported outcomes from the INPULSIS® trials"}],"recId":"1693850524","id":{"eki":["1693850524"],"doi":["10.1186/s12931-020-1298-1"]},"name":{"displayForm":["Michael Kreuter, Wim A. Wuyts, Marlies Wijsenbeek, Sabrina Bajwah, Toby M. Maher, Susanne Stowasser, Natalia Male, Wibke Stansen, Nils Schoof, Leticia Orsatti and Jeffrey Swigris"]},"note":["Gesehen am 02.04.2020"],"physDesc":[{"extent":"12 S."}],"relHost":[{"pubHistory":["1.2000 -"],"origin":[{"dateIssuedKey":"2001","dateIssuedDisp":"2001-","publisherPlace":"London","publisher":"BioMed Central"}],"recId":"326646485","id":{"issn":["1465-993X"],"zdb":["2041675-1"],"eki":["326646485"]},"title":[{"title_sort":"Respiratory research","title":"Respiratory research"}],"disp":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib analyses of patient-reported outcomes from the INPULSIS® trialsRespiratory research","language":["eng"],"note":["Gesehen am 04.08.22"],"part":{"year":"2020","volume":"21","text":"21(2020) Artikel-Nummer 36, 12 Seiten","extent":"12"},"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"language":["eng"],"origin":[{"dateIssuedDisp":"30 January 2020","dateIssuedKey":"2020"}]} | ||
| SRT | |a KREUTERMICHEALTHRELA3020 | ||